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Background: (−)-Epigallocatechin-3-gallate (EGCG), the most abundant catechin found in green tea, effectively
reduces body weight and tissue and blood lipid accumulation. To explore the mechanism by which EGCG inhibits
cellular lipid accumulation in free fatty acid (FFA) induced HepG2 cell culture, we investigated the proteome change
of FFA-induced HepG2 cells exposed to EGCG using two-dimensional gel electrophoresis and mass spectrometry.
Results: In this study, 36 protein spots showed a significant change in intensity by more than 1.5-fold from the control
group to the FFA group and from the FFA group to the FFA + EGCG group. Among them, 24 spots were excised from
gels and identified by LC-MS/MS. In total, 18 proteins were successfully identified. All identified proteins were involved
in lipid metabolism, glycometabolism, antioxidant defense, respiration, cytoskeleton organization, signal transduction,
DNA repair, mRNA processing, iron storage, or were chaperone proteins. This indicated that these physiological
processes may play roles in the mechanism of inhibition of lipid accumulation by EGCG in FFA-induced HepG2 cells.
Western blotting analysis was used to verify the expression levels of differentially expressed proteins, which agree with
the proteomic results.
Conclusions: From the proteomic analysis, we hypothesized that EGCG reduced cellular lipid accumulation in
FFA-induced HepG2 cells through the activation of AMP-activated protein kinase (AMPK) resulting from the generation
of reactive oxygen species (ROS). The induction of ROS may be a result of EGCG regulation of the antioxidant defense
system. Activation of AMPK shifted some FFA toward oxidation, away from lipid and triglyceride storage, and
suppressed hepatic gluconeogenesis. The findings of this study improve our understanding of the molecular
mechanisms of inhibition of lipid accumulation by EGCG in HepG2 cells.
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Nonalcoholic fatty liver disease (NAFLD), defined by ex-
cessive liver fat accumulation related to metabolic syn-
drome, is a leading cause of progressive liver disease.
NAFLD is a clinicopathological term that encompasses a
disease spectrum ranging from simple lipid accumulation
in hepatocytes (hepatic steatosis) to hepatic steatosis with
inflammation (steatohepatitis), fibrosis, and cirrhosis [1].* Correspondence: luoga@mail.tsinghua.edu.cn
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reproduction in any medium, provided the orExcess hepatic lipid accumulation is associated with nutri-
tional factors, drugs, and multiple genetic defects in en-
ergy metabolism.
Green tea is widely consumed throughout the world, es-
pecially in East Asian countries. Research indicates that
green tea is beneficial to health and many components of
tea have specific health-promoting effects [2,3]. Studies
have suggested that (−)-epigallocatechin-3-gallate (EGCG),
the most abundant catechin found in green tea, could ef-
fectively reduce body weight and tissue and blood fat ac-
cumulation [4,5]. In high-fat-fed mice, EGCG decreased
liver weight, liver triglycerides, plasma alanine aminotrans-
ferase concentrations, lipid accumulation in hepatocytesThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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nonalcoholic steatohepatitis through its effect on lipid me-
tabolism [7]. EGCG treatment could effectively reduce
fatty liver incidence, liver damage, and liver triglyceride
levels in Male C57BL/6J mice fed with a high-fat,
Western-style diet [8]. These beneficial effects of EGCG
are associated with decreased lipid absorption and reduced
levels of inflammatory cytokines. Previous studies have
suggested that EGCG and green tea might modulate ex-
pression of lipid metabolism-related genes. EGCG treat-
ment up-regulated several genes related to fat oxidation
and thermogenesis, including liver acyl-CoA oxidase
(AOX), medium-chain acyl-CoA dehydrogenase (MCAD),
muscle uncoupling protein-2 (UCP2) and uncoupling
protein-3 (UCP3), and fatty acid translocase [9-11]. More-
over, EGCG treatment down-regulated several genes re-
lated to fatty acid synthesis and storage in the liver and
white adipose tissue, including acetyl-CoA carboxylase
(ACC), fatty acid synthase (FAS), malic enzyme (ME),
glucose-6-phosphate dehydrogenase (G6PDH), glycerol-3
-phosphate dehydrogenase (G3PDH), and stearoyl-CoA
desaturase-1 (SCD1) [12-15].
Despite the amount of work on EGCG, there is little
proteomic information available on EGCG inhibiting lipid
accumulation in free fatty acid (FFA) induced HepG2 cells.
To investigate the inhibitory effect of EGCG on FFA-
induced lipid accumulation, HepG2 cells were exposed to
FFA co-treated with 50 μM EGCG. The proteome changes
of FFA-induced HepG2 cells were investigated by two-
dimensional gel electrophoresis (2-DE) combined with
matrix-assisted laser desorption ionization time-of-flight
mass spectrometry (MALDI-TOF/TOF MS). The object-
ive of this study was to obtain an improved understanding
of the mechanism by which EGCG inhibits lipid accumu-
lation in FFA-induced HepG2 cells.
Results
Effect of EGCG on FFA-induced intracellular lipid
accumulation in HepG2 cells
Fatty liver results from an imbalance between lipid avail-
ability and lipid metabolism. Palmitic and oleic acids are
the most abundant FFA in liver triglycerides in both nor-
mal subjects and patients with NAFLD [16]. Exposure of
HepG2 cells to exogenous FFA leads to significant intra-
cellular lipid accumulation [17]. HepG2 cells loaded with
1 mM FFA mixture (oleic acid [OA] and palmitic acid
[PA], 2:1) mimics benign chronic steatosis in humans
[18]. As shown in Figure 1A, the intracellular lipid con-
tent could be significantly lowered by treatment with
50 μM EGCG. This suggested that EGCG could signifi-
cantly inhibit FFA-induced intracellular lipid accumula-
tion in HepG2 cells. This result was also confirmed by
the quantification of intracellular triglycerides and chol-
esterol contents. In Figure 1B, EGCG treatment showedsignificantly lower triglyceride levels (p ≤ 0.05). The con-
tent of cholesterol was also lowered but not significantly.
The effects of EGCG on FFA-stimulated HepG2 cell via-
bility were examined by MTT assay and annexin V stain-
ing. The results showed that cell viability was not
compromised by 50 μM EGCG treatment after 24 h of
exposure (Figure 1C and D).
Change in protein abundance in the three groups
To explore the inhibitory effect of EGCG on FFA-induced
lipid accumulation in HepG2 cells, the proteomes of the
control, FFA-induced (FFA) and FFA-induced co-treated
with 50 μM EGCG groups (FFA + EGCG) were analyzed
by 2-DE (Figure 2). Among the tested samples, more than
800 protein spots were reproducibly detected with
PDQuest 8.0.1 software on Coomassie Brilliant Blue
(CBB) G-250-stained gels. The control and FFA + EGCG
groups had 142 and 151 protein spots that showed a sig-
nificant change in expression level in when compared with
the FFA group, respectively. Moreover, 36 protein spots
showed a significant change in intensity by more than 1.5-
fold from the control group to the FFA group and from
the FFA group to the FFA + EGCG group. Among them,
24 spots that changed at least 2.0-fold were excised from
gels and identified by MALDI-TOF/TOF MS. In total, 18
protein spots were successfully identified and the results
are summarized in Table 1. The functions of the differen-
tially expressed proteins were obtained using their protein
accession numbers from the SwissProt/NCBI protein
function summary. All identified proteins in this study
were involved in multiple functional groups (Table 1), in-
cluding lipid metabolism, glycometabolism, antioxidant
defense, respiration, cytoskeleton organization, signal
transduction, DNA repair, mRNA processing, and iron
storage, or were chaperone proteins.
Validation of differentially expressed proteins by western
blotting
Western blotting analysis was performed in triplicate to
confirm the differentially expression proteins found in the
proteomic analysis. FFA-induced HepG2 cells were treated
with 50 μM EGCG for 24 h. Equal amounts of total pro-
teins from different treated cells were used for western
blotting analysis. The results (Figure 3) suggested that the
expressed levels of peroxiredoxin-6 (Prdx6) and galacto-
kinase (GALK) were significantly lower (p ≤ 0.05) and suc-
cinate dehydrogenase flavoprotein subunit (SDHA) was
significantly higher (p ≤ 0.05) in the FFA + EGCG group
compared with the FFA group. Therefore, the western blot-
ting results agree with the proteomic results.
Discussion
Lipid accumulation is the main cause of NAFLD, which
results in fatty tissue degeneration [1,19]. This lipid
Figure 1 EGCG reduced FFA-induced intracellular lipid accumulation in HepG2 cells. Lipid content detected by a quantitative Oil Red O
dye method (A), Triglyceride and cholesterol levels in FFA-overloaded HepG2 cells in different treatment groups (B), The effect of EGCG on FFA-
overloaded HepG2 cells. Proliferation and apoptosis were assessed by MTT assay (C) and PI/annexin V staining (D).
Figure 2 Comparison of 2-D electrophoresis analysis of the proteins expressed in FFA-stimulated HepG2 cells derived from different
treatment groups. Control (A), FFA (B), FFA + EGCG (C). Proteins that exhibited a significant expression change (≥ 1.5-fold, p≤ 0.05) from the
control group to FFA group while from the FFA group to FFA + EGCG group are labeled in the figures.
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402 Keratin 1 H6VRF8 66184/8.15 118 13 Cytoskeleton
1210 Lysosomal protective
protein
P10619 34065/5.49 211 11 Glycometabolism
1217 14-3-3 protein gamma P61981 28325/4.80 350 30 Signal transduction
1311 Ubiquitin thioesterase
OTUB1
Q96FW1 26652/5.22 331 31 DNA repair
2307 Serine/arginine-rich
splicing factor 7
Q16629 26224/11.77 161 15 mRNA processing
3111 Probable G-protein
coupled receptor 179
Q6PRD1 260635/5.54 63 6 Signal transduction
3208 Prohibitin Q6PUJ7 29859/5.57 154 23 Chaperone proteins
3214 C447E6.1 (Nucleotide
binding protein 1)
Q2YS46 28604/5.89 65 16 Chaperone proteins
4116 Ferritin light chain P02792 18818/5.65 158 36 Iron storage
4201 Phosphoserine
phosphatase





P45954 44681/5.83 69 12 Lipid metabolism
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P62136 38229/5.94 239 29 Protein phosphorylation
5414 Galactokinase P51570 42702/6.04 131 14 Glycometabolism




Q15102 25832/6.33 136 26 Lipid metabolism




P31040 73672/7.06 170 25 Respiration
8012 Cofilin-1 P23528 18719/8.22 128 31 Signal transduction
a SwissProt accession number.
b A: control group. B: FFA group. C: FFA + EGCG (50 μM) group.
Figure 3 Validation of Prdx6, GALK, and SDHA expression
levels in HepG2 cells by Western blotting. The expression levels
of Prdx6, GALK and SDHA in the control, FFA and FFA + EGCG
groups were detected by Western blotting. β-actin was used as a
loading control. Similar results were found in the three independent
experiments and the representative results are shown.
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between lipogenesis and lipolysis metabolism causing
eventual lipoperoxidative stress and hepatic injury [20].
Previous studies suggest that the inhibitory action of
EGCG on lipid accumulation is mediated via the AMP-
activated protein kinase (AMPK) pathway [21-23]. Acti-
vation of AMPK can induce ATP generation through
glycolysis and β-oxidation, and suppress fatty acid and
cholesterol syntheses, and gluconeogenesis [24]. How-
ever, the inhibitory effect of EGCG on FFA-induced
intracellular lipid accumulation at the proteomic level
has not been investigated. In this study, we reported a
comprehensive proteome, which deduced the target
genes of EGCG as well as its inhibitory effect on lipid
accumulation in FFA-induced HepG2 cells. Eighteen dif-
ferentially expressed proteins were successfully identi-
fied. These proteins are involved in lipid metabolism,
glycometabolism, antioxidant defense, respiration, cyto-
skeleton organization, signal transduction, DNA repair,
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proteins. This indicates that these physiological processes
may play a role in the mechanism by which EGCG inhibits
cellular lipid accumulation in FFA-induced HepG2 cells.
Proteins involved in redox regulation and energy
metabolism
After treatment with EGCG, two differentially expressed
proteins related to redox and respiratory regulation were
identified in HepG2 cells. Prdx6 is the sixth mammalian
member of the peroxiredoxin family, which has an im-
portant role in antioxidant defense [25,26]. Several stud-
ies reported that an increase in reactive oxygen species
(ROS) could lead to AMPK activation [27,28]. EGCG
significantly induced generation of ROS and reduced
glutathione (GSH) in cells [21-23]. AMPK is thought to
be a novel target for the treatment of obesity and type II
diabetes [29]. Activation of AMPK in liver and skeletal
muscle leads to the stimulation of fatty acid oxidation
and inhibition of lipogenesis, glucose production and
protein synthesis [30,31]. However, these effects could
be eliminated by ROS scavenger, N-acetylcysteine, treat-
ment [22,23,28]. In our proteomic experiment, Prdx6
was down-regulated by EGCG treatment. This may be a
reason for the increasing ROS levels that lead to AMPK
activation, preventing lipid accumulation in cells. Suc-
cinate dehydrogenase (SDH or ubiquinone) is an enzyme
that controls the transcription of metabolism-related
genes in mitochondria and promotes metabolism of glu-
cose and lipids [32,33]. SDH is related to oxidative me-
tabolism and is an indicator of oxidative capacity in cells
[34]. Prior studies have found that a reduction in oxida-
tive enzymes is correlated with a reduced capacity for
lipid oxidation and increased risk for obesity [35,36].
The mRNA expression levels of SDH are reduced in
mice with type II diabetes mellitus and obesity [37]. Sev-
eral studies have also shown that weight loss and exer-
cise could result in a significant increase in SDH activity
[38,39]. Our proteomic analysis showed that SDHA was
up-regulated by EGCG treatment in FFA-induced
HepG2 cells, indicating that EGCG increased lipid oxi-
dation by enhancing energy expenditure and fat oxida-
tion in the mitochondria of HepG2 cells.
Proteins involved in lipid metabolism
Proteins involved in lipid metabolism were changed sig-
nificantly by EGCG treatment in HepG2 cells. Platelet-
activating factor acetylhydrolase (PAFAH), a unique
member of the phospholipase A2 superfamily, is charac-
terized by its ability to specifically hydrolyze platelet-
activating factor (PAF) and glycerophospholipids [40].
PAF is a potent pro-inflammatory phospholipid that ac-
tivates cells involved in inflammation and stimulates
ROS generation [41-43]. Down-regulation of platelet-activating factor acetylhydrolase IB subunit gamma
(PAFAH1B3) by EGCG treatment might lead to an in-
crease of PAF, which could stimulate the generation of
ROS and activating AMPK in HepG2 cells. Short/
branched-chain acyl-CoA dehydrogenase (SBCAD) cata-
lyzes the first step in the mitochondrial β-oxidation
of L-2-methylated short acyl-CoA compounds [44].
SBCAD deficiency is characterized by accumulation of 2-
methylbutyrylglycine (2MBG), which induced an increase
of lipid oxidation and a decrease of antioxidant defenses
(decreased GSH) in rat [45]. In our proteomic experiment,
SBCAD was down-regulated in the EGCG-treated group.
This might result in a decrease of antioxidant defense and
a high level of cellular ROS, which could activate AMPK
to prevent cellular lipid accumulation.
Proteins involved in glycometabolism
Two proteins involved in glycometabolism were down-
regulated by EGCG treatment. GALK catalyzes the phos-
phorylation of α-galactose to galactose-1-phosphate in the
second step of the Leloir pathway, a metabolic pathway
found in most organisms for the catabolism of β-galactose
to glucose-1-phosphate [46]. Glucose-1-phosphate could
be metabolized to glucose-6-phosphate providing sub-
strate for the pentose phosphate pathway, which generates
ribose-5-phosphate and NADPH for the biosynthesis of
fatty acids and sterols [47]. A study reported that unsatur-
ated fatty acids could increase the activation of galacto-
kinase and galactose-1-phosphate uridyltransferase, and
stimulate sterol biosynthesis from galactose [48]. Down-
regulation of galactokinase reduces ribose-5-phosphate
and NADPH from the pentose phosphate pathway,
resulting in a reduction of the biosynthesis of fatty acids
and sterols in FFA-induced HepG2 cells. Lysosomal pro-
tective protein (PPCA) appears to be essential for the ac-
tivity of β-galactosidase, which catalyzes the hydrolysis of
β-galactosides into β-galactose and glucoside. PPCA asso-
ciates with β-galactosidase and exerts a protective function
necessary for its stability and activity [49]. Down-
regulation of PPCA could reduce the activity of β-
galactosides and decrease β-galactose for the Leloir
pathway, inhibiting the biosynthesis of fatty acids and ste-
rols from galactose [47,48].
Proteins involved in biological regulation and signal
transduction
Some proteins involved in biological regulation and sig-
nal transduction were also identified in HepG2 cells, in-
cluding serine/threonine protein phosphatase-alpha
catalytic subunit (PP-1A), phosphoserine phosphatase
(PSP), 14-3-3 protein gamma and prohibitin (PHB). PP-
1A and PSP belong to the phosphoprotein phosphatase
family, which remove the phosphate from the serine or
threonine residues of phosphoproteins [50]. Previous
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transcription of the FAS gene was markedly reduced by
okadaic acid, an inhibitor of protein serine/threonine
phosphatases 1 (PP1) and PP2A, and by AICAR, a cell-
permeable activator of the AMPK [51]. These results in-
dicated that the reduction of the FAS gene involves a
phosphorylation/dephosphorylation mechanism and
AMPK activation. Therefore, down-regulation of PP-1A
and PSP might indicate an inhibition of lipid biosyn-
thesis and an activation of AMPK in HepG2 cells by
EGCG treatment. 14-3-3 protein gamma belongs to the
14-3-3 protein family, which has the ability to bind many
functionally diverse signaling proteins, including kinases,
phosphatases, and transmembrane receptors [52,53].
The transcriptional co-activator transducer of regulated
CREB activity 2 (TORC2) is a pivotal component of glu-
coneogenesis [54]. Phosphorylated TORC2 is seques-
tered in the cytoplasm via a phosphorylation-dependent
interaction with 14-3-3 proteins and degraded by 26S
proteasome to inhibit the gluconeogenic program [55].
A report suggested that inhibition of enhanced gluco-
neogenesis induced by high-fat and high-fructose diet
could improve lipid metabolism and hepatic steatosis in
mice [56]. Thus, up-regulation of 14-3-3 protein by
EGCG treatment in FFA-induced HepG2 cells might in-
dicate that the hepatic steatosis induced by overloaded
FFA was improved through inhibition of gluconeogene-
sis. PHB comprise two evolutionarily conserved proteins,
prohibitin-1 (PHB1) and prohibitin-2 (PHB2), and are
present in a high molecular-weight complex in the inner
membrane of mitochondria [57,58]. PHB1 decreased
insulin-stimulated oxidation of glucose and fatty acids,
implying that PHB1 may play a role in promoting fat ac-
cumulation [59]. A microarray analysis showed that the
expression levels of PHB were increased during 3T3-L1Figure 4 A simple model of the proposed mechanism by which EGCG
Arrowheads indicate the direct or indirect interactions. The up-regulated p
marked with blue.cell adipogenesis [60]. Several studies showed that deple-
tion of PHB1 or PHB2 in C. elegans or 3T3-L1 cells
could significantly decrease adipose accumulation and
adipogenesis [61]. In the current study, EGCG decreased
the expression of PHB, which might be one of the rea-
sons that EGCG could inhibit lipid accumulation in
FFA-induced HepG2 cells.
Conclusions
In summary, this study demonstrates that EGCG can sig-
nificantly suppress the lipid accumulation in FFA-induced
HepG2 cells. Using a proteomic approach, we identified
18 differentially expressed proteins responsive to EGCG
treatment involving multiple cellular processes. From the
proteomic analysis, we supposed that EGCG reduced cel-
lular lipid accumulation in FFA-induced HepG2 cells
through the activation of AMPK resulting from the gener-
ation of ROS. The induction of ROS may be because
EGCG regulated the antioxidant defense system in HepG2
cells (Figure 4). Activation of AMPK shifted some FFA to-
ward oxidation, away from lipid and triglyceride storage,
and suppressed hepatic gluconeogenesis in HepG2 cells.
Findings of this study provide information to improve our
understanding of the molecular mechanisms of the inhib-
ition of lipid accumulation by EGCG in HepG2 cells.
Methods
Materials
All chemicals used were of analytic grade. EGCG was
obtained from Sigma (St. Louis, MO, USA), the purity of
EGCG was ≥95%. Oleic acid and palmitic acid were also
obtained from Sigma. Antibodies to β-actin and Prdx6
were obtained from GeneTex (Irvine, CA, USA). Anti-
bodies to SDHA and GALK were obtained from Abcam
(Cambridge, UK).inhibits lipid accumulation in FFA-induced HepG2 cells.
roteins are marked with red and the down-regulated proteins are
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Experiments were approved by the ethics committee of
Tsinghua University. HepG2 cells (human liver hepato-
cellular carcinoma cell line) were obtained from the cell
bank of the Type Culture Collection of Chinese Acad-
emy of Sciences, and were cultured in DMEM medium
(Thermo, South Logan, UT, USA) with 10% fetal calf
serum, 100 U/mL penicillin, 100 μg/mL streptomycin,
and 2 mM L-glutamine and kept at 37°C in a humidified
atmosphere (Nuaire, Plymouth, MN, USA) with 5%
CO2. To induce fat-overloading, HepG2 cells were ex-
posed to 1 mM of FFA mixture (OA / PA, 2:1) mixed
with 1% FFA-free bovine serum albumin [17,28,62].
Stock solutions of 50 mM FFA were prepared as
reported previously [63]. When the cells reached 70%
confluence, they were incubated in serum-free medium
for 24 h before treatments. Then, the cells were stimu-
lated with 1 mM FFA and co-treated with EGCG
for 24 h.
Cell proliferation and apoptosis assay
The effect of EGCG on cell proliferation was assessed
using MTT assay as previously reported [64]. Briefly,
HepG2 cells were plated in 96-well plates (5 × 103 cells/
well) and treated with 1 mM FFA with various concen-
trations of EGCG for 24 h. Then cells were incubated
with 100 μL MTT solution (0.5 mg/mL MTT in PBS
buffer) for 4 h. The absorbance was measured with a
Multiskan MK3 (Thermo) at 490 nm. Apoptotic cells
were detected using flow cytometry with PI/annexin V
staining [64]. Cells were seeded in six-well plates (4 ×
106 cells/well) and co-incubated with 0, 50, and 100 μM
of EGCG and 1 mM FFA for 24 h. After harvesting with
0.25% trypsin, cells were resuspended with 200 μL bind-
ing buffer and incubated with 10 μL Annexin V-FITC
and 5 μL PI for 15 min at room temperature. Sample so-
lutions were adjusted to 500 μL using binding buffer and
analyzed with a FACScan flow cytometer (Becton Dick-
inson Biosciences, San Jose, CA, USA) within an hour of
sample preparation. The data were analyzed by
Modfit3.0 (Verity Software House, Topsham, ME, USA).
All treatments were performed in triplicate.
Oil Red O staining
The Oil Red O (ORO) staining was according to
Amacher et al. [65,66]. Briefly, the cells were washed
twice with ice-cold PBS and fixed with 10% formalin for
1 h, and stained with Oil Red O solution for 2 h at room
temperature. After staining, cells were washed twice with
distilled water to remove unbound dye. To quantitate
the intracellular lipid content levels, isopropanol was
added to each sample shaken at room temperature for
5 min, and samples were read spectrophotometrically
at 520 nm.Triglycerides and cholesterol assay
For lipidic determinations, homogenates from cells were
extracted according to a Heider et al. [67]. Briefly, each
sample was homogenized with isopropyl alcohol. The
resulting mixture was shaken at room temperature for
1 h and then centrifuged at 1200 × g for 10 min. The
supernatant was collected for analysis of hepatic TG and
TC content. The residue was dissolved in 0.1 M sodium
hydroxide and an aliquot was taken for protein determin-
ation with an RC DC Protein Assay Kit (Bio-Rad,
Hercules, CA, USA). Triacylglycerol and cholesterol were
measured using enzymatic method kits (Cell Biolabs, Inc.
San Diego, CA, USA) according to the manufacturer’s
instructions.
Protein extract and sample preparation for 2-DE
The HepG2 cells were harvested by trypsinization and
washed twice with ice-cold PBS buffer. The cells were
lysed in lysis buffer (7 M urea, 2 M thiourea, 4% [w/v]
CHAPS, 65 mM DTT, 2% [v/v] Bio-Lyte pH [3-10], 2%
protease inhibitor cocktail), mixed by vortexing, kept in
an ice bath for 2 h, then sonicated in an ice bath. The
sample was clarified by centrifugation at 15000 × g for
1 h at 4°C, and the supernatants stored at −80°C until
use for 2-DE. Protein content was quantified using the
RC DC Protein Assay Kit (Bio-Rad).
2-DE and image analysis
About 1.3 mg protein dissolved in 350 μL rehydration
buffer was applied to IPG strips (17 cm, pH 3–10, Bio-
Rad), which was allowed to rehydrate for 13 h at 50 V
(20°C). Subsequently, isoelectric focusing (IEF) was
performed at using a Protean IEF Cell (Bio-Rad) under
the following conditions: 250 V for 1 h with a slow in-
crease in voltage, 500 V for 1 h with a slow increase in
voltage, 1000 V for 1 h with a slow increase in voltage,
10000 V for 5 h with a linear increase in voltage, and
maintained at 10000 V until 60000 Volt-hours (Vh) was
reached. After IEF, the strips were equilibrated for
15 min in equilibration buffer I (0.375 M Tris–HCl pH
8.8, 6 M urea, 2% SDS, 20% glycerol, 1% DTT), then re-
equilibrated in buffer II containing 2.5% iodoacetamide
instead of DTT for 15 min. The strips were transferred
onto 12% polyacrylamide gels for SDS-PAGE. Electro-
phoresis was performed using the PROTEAN II xi Cell
system (Bio-Rad) at 10 mA per gel for 30 min, followed
by 30 mA until the bromophenol blue marker reached
the end of the gel. Gels were run in triplicate for each
sample. The gels were stained with modified colloidal
CBB G-250 [68] and were scanned using Quantity One
4.6.9 (Bio-Rad) with a Bio-Rad GS800 scanner. Image
and statistical analysis was performed with PDQuest
8.0.1 (Bio-Rad) as previously reported [69]. In the quan-
titative analysis, 1.5 and 0.5 were chosen as the upper
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nificance level of 95% were used for the statistical ana-
lysis of the gels. Each sample was performed in triplicate
gels.
Protein in-gel digestion and identification
Protein spots were manually excised from the gel, and
digested as previously reported [69]. Mass spectrometric
analysis was performed with an Ultraflex MALDI TOF/
TOF mass spectrometer (Bruker Daltonik, Bremen,
Germany), under the control of FlexControl™ 2.2 soft-
ware (Bruker Daltonik GmbH). The TOF spectra were
recorded in the positive ion reflector mode in a mass
range from 800–4000 Da. Ten subspectra with 30 shots
per subspectrum were accumulated to generate one
main TOF spectrum. After automated assessment of the
search results with MASCOT software (Matrix Science,
London, UK), the samples not unambiguously identified
by PMF were automatically submitted to MS/MS ana-
lysis using the LIFT technology in TOF/TOF. A max-
imum of three strongest peaks of the TOF MS spectrum
per sample were chosen for MS/MS analysis. Three
subspectra with 50 shots per subspectrum for precursor
ions and 15 subspectra with 50 shots per subspectrum
for fragment ions were accumulated to produce one
main MS/MS spectrum. After the automated analysis,
remaining unidentified samples were manually analyzed.
Database searching
Protein identification from MS/MS sequencing spectra
was accomplished using the MASCOT database search
engine (Matrix Science, London, UK). The searching pa-
rameters were set as follows: taxonomy, Homo sapiens;
database, NCBInr/Swiss-Prot; enzyme, trypsin; fixed
modifications, carbamidomethyl (C); variable modifica-
tions, oxidation (M); no restrictions on protein mass;
allow up to one missed cleavages. Mass values, Monoiso-
topic; Peptide Mass Tolerance was set as ±50 ppm; Frag-
ment Mass Tolerance was set as ±0.5 Da. Positive
protein identification was based on standard MASCOT
criteria for statistical analysis of the LC-MS/MS data.
The peptide assignments in the database search results
were manually inspected for validation.
Western blotting analysis
The HepG2 cells were harvested by trypsinization and
washed twice with ice-cold PBS buffer. The cells were
lysed in RIPA buffer (25 mM Tris–HCl pH 7.6, 150 mM
NaCl, 1% NP-40, 1% sodium deoxycholate, 0.1% SDS,
2% protease inhibitor cocktail). Equal amounts of pro-
tein were separated on a 12% SDS-polyacrylamide gel,
blotted onto a PVDF membrane, which was blocked for
1 h at 25°C with 5% wt/vol BSA/TBST (10 mM Tris
HCl, pH 7.4, 140 mM NaCl, 0.1% Tween-20) and thenincubated with the primary antibody for Prdx6 (1:3000),
SDHA (1:1000) and GALK (1:1000) at 4°C overnight.
After washing with TBST, the membranes were incu-
bated with the appropriate secondary antibodies for 1 h
at 37°C and detected by immuno-staining. After the
membranes were scanned, the signal intensity of each
band was determined using FluorChem FC2 (Alpha
Innotech Co., Ltd, San Leandro, CA, USA).Statistical analysis
All results were expressed as mean ± SD and analyzed
by student’s t-test. A p ≤ 0.05 was considered to be statis-
tically significant.
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